Effects of age and race on clinical response to acebutolol in essential hypertension

Data from three multicenter controlled clinical trials of acebutolol carried out in the United States were reviewed to determine the efficacy and safety of acebutolol in patients greater than or equal to 65 years and in black patients. In 54 elderly patients, acebutolol decreased diastolic blood pressure by 12.8 mm Hg, and 86.5% were classified as responders. Acebutolol was superior to placebo, propranolol, and hydrochlorothiazide in terms of response rate. In 56 black patients, acebutolol decreased diastolic blood pressure by 8.5 mm Hg, and 53% were classified as responders. Acebutolol was superior to placebo and propranolol but not as effective as hydrochlorothiazide in terms of response rate. Acebutolol was well tolerated in both patient populations.